New targeted pill shows promise for rare lung cancer mutation

NCT ID NCT05110196

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called capmatinib in 50 Indian adults with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 skipping mutation). The goal was to see how safe the drug is and how well it shrinks tumors. Participants took capmatinib pills, and researchers monitored side effects and cancer response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchial neoplasm carcinoma lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

Novartis Investigative Site

Gujarat, Gujarat, 380016, India
Novartis Investigative Site

Mangalore, Karnataka, 575002, India
Novartis Investigative Site

Thalassery, Kerala, 670103, India
Novartis Investigative Site

Trivandrum, Kerala, 695 011, India
Novartis Investigative Site

Bhopal, Madhya Pradesh, 462001, India
Novartis Investigative Site

Mumbai, Maharashtra, 400 012, India
Novartis Investigative Site

Mumbai, Maharashtra, 400056, India
Novartis Investigative Site

Nagpur, Maharashtra, 441108, India
Novartis Investigative Site

Pune, Maharashtra, 411040, India
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110029, India
Novartis Investigative Site

Bhubaneswar, Odisha, 751007, India
Novartis Investigative Site

Hyderabad, Telangana, 500004, India
Novartis Investigative Site

Varanasi, Uttar Pradesh, 221005, India
Novartis Investigative Site

Kolkata, West Bengal, 700 020, India
Novartis Investigative Site

Puducherry, 605006, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.